Wednesday, 25 Apr 2018

You are here

Using Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis

Researchers at Northwestern University have used ultrasound-guided tissue biopsy from the joints to analyze the genes of tissue macrophages with the hope that transcriptional profiling of synovial macrophages may be correlated with clinical parameters or drug responsiveness in rheumatoid arthritis (RA) patients.(Citation source: https://buff.ly/2FPmgKA)

This attempt at precision medicine is driven by the "trial and error" approach to RA therapy, low response or incomplete response to very good drugs and evidence showing no correlations with blood sampling or clinical parameters.

This was a multi-site study of 41 rheumatoid arthritis patients who underwent US-guided synovial biopsies.

Participating sites included Northwestern University; the University of Alabama at Birmingham; Washington University, Columbia University, Mayo Clinic and University of Michigan.

Whole tissue samples from RA patients had a high degree of transcriptional heterogeneity. However,  the transcriptional profile of isolated RA synovial macrophages highlighted a subpopulation of patients and identified six novel transcriptional modules that were associated with disease activity and therapy. 

In the next phase of research, investigators will do pre- and post treatment (6 weeks later) biopsies to identify predictor gene sequence that will clearly identify which patients respond to a particular therapy.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Review: Take Two for Baricitinib

FDA staff remain worried about the safety of baricitinib, an oral JAK inhibitor intended for treatment of rheumatoid arthritis, according to briefing documents prepared for an advisory committee meeting on Monday.

Shared Epitope - Smoking Pathogenic Link Clarified

Proceedings of the National Academy of Sciences (PNAS) has published new research on the mechanistic link between the rheumatoid arthritis (RA) "shared epitope" (SE) risk alleles and environmental triggers such as cigarette smoke that leads to joint inflammation and bony destruction. 

Kineret Approved for Still's Disease in EU

SOBI has announced that Kineret (anakinra) has been approved by the European Commission (EC) for the treatment of Still’s disease (Systemic Juvenile Idiopathic Arthritis [SJIA] and Adult-Onset Still’s Disease [AOSD]), in all 28 European Union (EU) member states. Still's disease is a rare systemic multi-organ disorder of auto-inflammatory nature that affects approximately 25,000 children and adults in the EU.

Mayo and UAB Awarded $1 million Grant for Patient Research

CreakyJoints and Pfizer have selected the Mayo Clinic and the University of Alabama at Birmingham (UAB) to each receive a $500K research award (funded by Pfizer Independent Grants) for Learning & Change.

Grants submitted from both centers haved focused on shared decision making between rheumatoid arthritis (RA) and health care providers.

Defining Refractory Rheumatoid Arthritis

Dr. Maya Buch from Leeds has a thoughtful Viewpoint article in Annals of Rheumatic Disease on how to consider and manage the refractory or difficult rheumatoid arthritis (RA) patient.

Despite advances in our understanding the pathogenesis of RA and the advent of novel biologic and small molecule disease-modifying antirheumatic drugs, we still have a regretful proportion of patients who are refractory to our best therapies.